Track 10: Challenges in Rare Diseases Treatment

There are around 7,000 rare diseases, which from a regulatory outlook are defined as those diseases where there are less than 200,000 patients in the US or that affect no more than five in 10,000 of the general population in the EU. Orphan drugs are medicinal products envisioned for diagnosis, prevention, and treatment of life-threatening rare diseases. They are "orphans" because the pharmaceutical industry has little interest under normal market conditions in developing and marketing drugs intended for only a small number of patients suffering from very rare conditions.

 

    Related Conference of Track 10: Challenges in Rare Diseases Treatment

    June 09-10, 2020

    10th European Epidemiology and Public Health Congress

    Istanbul, Turkey
    July 22-23, 2020

    10th World Congress on Rare Diseases and Orphan Drugs

    Barcelona, Spain
    August 19-20, 2020

    European Summit on HIV, STD and STIs

    Milan, Italy
    September 28-29, 2020

    13th Global Infections Conference

    Singapore
    October 5-6, 2020

    12th Euro-Global Conference on Infectious Diseases

    Vienna, Austria
    November 05-06, 2020

    9th Asia Pacific STD and Infectious Diseases Congress

    Tokyo, Japan
    February 15-16, 2021

    8th International Congress on Infectious Diseases

    London, UK
    February 22-23, 2021

    4th Global Experts Meeting on Infectious Diseases

    Singapore City, Singapore

    Track 10: Challenges in Rare Diseases Treatment Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in